E202 / TCRCure - LARVOL DELTA

HPV16 E6 TCR T Cells for Cervical Carcinoma (clinicaltrials.gov) - P1/2 | N=5 | Terminated | Sponsor: TCRCure Biopharma Ltd. | N=18 ➔ 5 | Trial completion date: Aug 2025 ➔ Jan 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2024 ➔ Jan 2026; Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cervical Cancer • Oncology • Solid Tumor

HPV16 E6 TCR T Cells for Cervical Carcinoma (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: TCRCure Biopharma Ltd. | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

HPV16 E6 TCR T Cells for Cervical Carcinoma (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: TCRCure Biopharma Ltd. | Trial primary completion date: Mar 2023 ➔ Dec 2023

Metastases • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

HPV16 E6 TCR T Cells for Cervical Carcinoma (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: TCRCure Biopharma Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Sep 2022 ➔ Mar 2023

Enrollment open • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

HPV16 E6 TCR T Cells for Cervical Carcinoma (clinicaltrials.gov) - P1/2 | N=18 | Not yet recruiting | Sponsor: TCRCure Biopharma Ltd.

New P1/2 trial • Cervical Cancer • Oncology • Solid Tumor